- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 317/62 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
Patent holdings for IPC class C07D 317/62
Total number of patents in this class: 71
10-year publication summary
|
9
|
2
|
4
|
4
|
4
|
2
|
4
|
7
|
5
|
3
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | 163 |
6 |
| The University of Queensland | 660 |
6 |
| Novartis AG | 10849 |
4 |
| Tasly Pharmaceutical Group Co., Ltd. | 119 |
3 |
| Lario Therapeutics Ltd | 13 |
3 |
| CalciMedica, Inc. | 81 |
2 |
| CHDI Foundation, Inc. | 108 |
2 |
| Kissei Pharmaceutical Co., Ltd. | 183 |
2 |
| Ligand Pharmaceuticals Incorporated | 169 |
2 |
| Mitsubishi Gas Chemical Company, Inc. | 3465 |
2 |
| Omeros Corporation | 307 |
2 |
| H. Lundbeck A/S | 1247 |
2 |
| United Kingdom Research and Innovation | 364 |
2 |
| Metrion Biosciences Limited | 10 |
2 |
| F. Hoffmann-La Roche AG | 7925 |
1 |
| Hoffmann-La Roche Inc. | 3418 |
1 |
| Boehringer Ingelheim International GmbH | 4650 |
1 |
| Syngenta Participations AG | 1903 |
1 |
| Bayer Animal Health GmbH | 221 |
1 |
| Bayer Healthcare AG | 83 |
1 |
| Other owners | 25 |